Gal-3 immunohistochemistry has been reported to assist the diagnosis of FVPTC [29,35]; however, the role of Gal-3 expression as an ancillary marker in reclassification to NIFTP has not yet been determined. The gene discussed is LGALS3; the disease is follicular variant thyroid gland papillary carcinoma.